Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

Federal funding opportunity PAR-25-327 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes October 8, 2027

Program funding history

Synopsis

Who can apply

• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• State governments
• Special district governments
• Public housing authorities/Indian housing authorities
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• For profit organizations other than small businesses
• Independent school districts
• Native American tribal organizations (other than Federally recognized tribal governments)
• Public and State controlled institutions of higher education
• Small businesses
• County governments
• Private institutions of higher education
• City or township governments
• Native American tribal governments (Federally recognized)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

How to apply

Similar grants

• Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
  PAR-25-024 · National Institutes of Health · closes January 7, 2028
• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
  PAR-25-059 · National Institutes of Health · closes October 20, 2027
• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
  PAR-25-060 · National Institutes of Health · closes October 20, 2027
• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
  PAR-25-225 · National Institutes of Health · closes October 20, 2027
• Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
  PAR-24-293 · National Institutes of Health · closes August 18, 2027
• Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
  RFA-NS-26-002 · National Institutes of Health